Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.

about

Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients.

P2860

Q37447650-20137EFB-8056-4AB9-813A-4D5F1C921E13

P2860

Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.

Item

http://www.wikidata.org/entity/Q35670802

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prevalence and Risk Factors fo ...... in the Swiss IBD Cohort Study.

@ast

Prevalence and Risk Factors fo ...... in the Swiss IBD Cohort Study.

@en

type

Item

label

Prevalence and Risk Factors fo ...... in the Swiss IBD Cohort Study.

@ast

Prevalence and Risk Factors fo ...... in the Swiss IBD Cohort Study.

@en

prefLabel

Prevalence and Risk Factors fo ...... in the Swiss IBD Cohort Study.

@ast

Prevalence and Risk Factors fo ...... in the Swiss IBD Cohort Study.

@en

P1476

Prevalence and Risk Factors fo ...... in the Swiss IBD Cohort Study.

@en

P2093

Alain M Schoepfer

http://www.w3.org/2001/XMLSchema#string

Alex Straumann

http://www.w3.org/2001/XMLSchema#string

Ekaterina Safroneeva

http://www.w3.org/2001/XMLSchema#string

Nicolas Fournier

http://www.w3.org/2001/XMLSchema#string

Stephan R Vavricka

http://www.w3.org/2001/XMLSchema#string

P2860

The burden of inflammatory bowel disease in Europe

Infliximab for induction and maintenance therapy for ulcerative colitis

Epidemiology and natural history of inflammatory bowel diseases

Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Frequency of glucocorticoid resistance and dependency in Crohn's disease

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009 - results from the IBD cohort of the Uppsala Region (ICURE).

Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

P304

1348-1358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MIB.0000000000000368

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gerhard Rogler

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25806845

http://www.w3.org/2001/XMLSchema#string

P932

4450965

http://www.w3.org/2001/XMLSchema#string

Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.

about

P2860

P2860

Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932